CY1108319T1 - Νεος συνδυασμος μεταξυ της αγομελατινης και ενος αναστολεα της επανασυλληψης της νοραδρεναλινης και φαρμακευτικες συνθεσεις που τον περιεχουν - Google Patents

Νεος συνδυασμος μεταξυ της αγομελατινης και ενος αναστολεα της επανασυλληψης της νοραδρεναλινης και φαρμακευτικες συνθεσεις που τον περιεχουν

Info

Publication number
CY1108319T1
CY1108319T1 CY20081100955T CY081100955T CY1108319T1 CY 1108319 T1 CY1108319 T1 CY 1108319T1 CY 20081100955 T CY20081100955 T CY 20081100955T CY 081100955 T CY081100955 T CY 081100955T CY 1108319 T1 CY1108319 T1 CY 1108319T1
Authority
CY
Cyprus
Prior art keywords
agomelatin
noradrenaline
inhibitor
rehabilitation
pharmaceutical compositions
Prior art date
Application number
CY20081100955T
Other languages
English (en)
Inventor
Elisabeth Mocaer
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1108319T1 publication Critical patent/CY1108319T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Συνδυασμός ο οποίος περιέχει την αγομελατίνη ή Ν-[2-(7-μεθοξυ-1-ναφθύλ)αιθύλ] ακεταμίδιο εν συνδυασμώ με έναν αναστολέα της επανασύλληψης της νοραδρεναλίνης. Φάρμακα.
CY20081100955T 2005-09-09 2008-09-04 Νεος συνδυασμος μεταξυ της αγομελατινης και ενος αναστολεα της επανασυλληψης της νοραδρεναλινης και φαρμακευτικες συνθεσεις που τον περιεχουν CY1108319T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0509206A FR2890564B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
EP06291421A EP1769798B1 (fr) 2005-09-09 2006-09-08 Nouvelle association entre l'agomélatine et un inhibiteur de la recapture de la noradrénaline et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CY1108319T1 true CY1108319T1 (el) 2014-02-12

Family

ID=36190808

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100955T CY1108319T1 (el) 2005-09-09 2008-09-04 Νεος συνδυασμος μεταξυ της αγομελατινης και ενος αναστολεα της επανασυλληψης της νοραδρεναλινης και φαρμακευτικες συνθεσεις που τον περιεχουν

Country Status (39)

Country Link
US (1) US7622505B2 (el)
EP (1) EP1769798B1 (el)
JP (2) JP5395998B2 (el)
KR (1) KR100863384B1 (el)
CN (1) CN1927205A (el)
AP (1) AP2615A (el)
AR (1) AR056056A1 (el)
AT (1) ATE404205T1 (el)
AU (1) AU2006209368B2 (el)
BR (1) BRPI0603759A (el)
CA (1) CA2558782C (el)
CY (1) CY1108319T1 (el)
DE (1) DE602006002210D1 (el)
DK (1) DK1769798T3 (el)
EA (1) EA011650B1 (el)
ES (1) ES2313590T3 (el)
FR (1) FR2890564B1 (el)
GE (1) GEP20094742B (el)
GT (1) GT200600408A (el)
HR (1) HRP20080535T3 (el)
JO (1) JO2521B1 (el)
MA (1) MA28505B1 (el)
ME (2) ME02758B (el)
MX (1) MXPA06010157A (el)
MY (1) MY142260A (el)
NO (1) NO338029B1 (el)
NZ (1) NZ549725A (el)
PE (1) PE20070429A1 (el)
PL (1) PL1769798T3 (el)
PT (1) PT1769798E (el)
RS (1) RS50631B (el)
SA (1) SA06270308B1 (el)
SG (1) SG131030A1 (el)
SI (1) SI1769798T1 (el)
TW (1) TWI324513B (el)
UA (1) UA83542C2 (el)
UY (1) UY29778A1 (el)
WO (1) WO2007028904A1 (el)
ZA (1) ZA200607562B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
CN102342924A (zh) * 2010-08-05 2012-02-08 北京本草天源药物研究院 一种含有阿戈美拉汀的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
IL163720A0 (en) * 2002-02-26 2005-12-18 Ortho Mcneil Pharm Inc Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
JP2004292445A (ja) * 2003-03-11 2004-10-21 Katsunori Nonogaki 糖尿病治療薬
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물

Also Published As

Publication number Publication date
JP2011088919A (ja) 2011-05-06
TW200744570A (en) 2007-12-16
TWI324513B (en) 2010-05-11
MA28505B1 (fr) 2007-04-03
ATE404205T1 (de) 2008-08-15
AR056056A1 (es) 2007-09-12
PT1769798E (pt) 2008-09-18
GT200600408A (es) 2007-05-21
AP2615A (en) 2013-03-14
CN1927205A (zh) 2007-03-14
RS50631B (sr) 2010-06-30
FR2890564A1 (fr) 2007-03-16
US20070060654A1 (en) 2007-03-15
BRPI0603759A (pt) 2007-05-15
ES2313590T3 (es) 2009-03-01
HRP20080535T3 (en) 2008-12-31
UY29778A1 (es) 2006-10-31
SI1769798T1 (sl) 2008-12-31
CA2558782A1 (fr) 2007-03-09
EP1769798B1 (fr) 2008-08-13
DK1769798T3 (da) 2008-11-24
KR20070029606A (ko) 2007-03-14
DE602006002210D1 (de) 2008-09-25
ME02758B (me) 2010-06-30
WO2007028904A1 (fr) 2007-03-15
EA200601410A1 (ru) 2007-04-27
CA2558782C (fr) 2012-05-15
ZA200607562B (en) 2008-05-28
NZ549725A (en) 2008-03-28
FR2890564B1 (fr) 2007-10-19
ME02767B (me) 2010-06-30
MY142260A (en) 2010-11-15
JP2007077147A (ja) 2007-03-29
JP5395998B2 (ja) 2014-01-22
EA011650B1 (ru) 2009-04-28
SG131030A1 (en) 2007-04-26
GEP20094742B (en) 2009-07-27
KR100863384B1 (ko) 2008-10-13
AU2006209368B2 (en) 2012-07-19
UA83542C2 (uk) 2008-07-25
SA06270308B1 (ar) 2011-10-08
AP2008004378A0 (en) 2008-04-30
NO338029B1 (no) 2016-07-25
US7622505B2 (en) 2009-11-24
PL1769798T3 (pl) 2008-12-31
AU2006209368A1 (en) 2007-03-29
JO2521B1 (en) 2010-03-17
PE20070429A1 (es) 2007-06-02
EP1769798A1 (fr) 2007-04-04
NO20064048L (no) 2007-03-12
MXPA06010157A (es) 2007-03-08

Similar Documents

Publication Publication Date Title
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
BRPI0409063A (pt) pró medicamentos de inibidor de pi-3 cinase
DOP2006000050A (es) Una formulación sólida de dosificación farmaceútica
HN2002000030A (es) Nueva sal succinato de o-desmetil-venlafaxina
UY30048A1 (es) Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
DK1638933T3 (da) N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer
CY1106749T1 (el) Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας
BRPI0518196A (pt) métodos e kits para o preenchimento asséptico de produtos
CY1113154T1 (el) Συνδυασμος του αναληπτικου modafinil και ενος αντικαταθλιπτικου για τη θεραπεια της καταθλιψης
CY1112433T1 (el) Συνθεση ζιμποτεντανης που περιεχει μαννιτολη και μικροκρυσταλλικη κυτταρινη
NO20071774L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av generalisert angstlidelse
CY1108319T1 (el) Νεος συνδυασμος μεταξυ της αγομελατινης και ενος αναστολεα της επανασυλληψης της νοραδρεναλινης και φαρμακευτικες συνθεσεις που τον περιεχουν
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
CY1111007T1 (el) Νεος συνδυασμος ενος αναστολεα του φλεβοκομβικου ρευματος if και ενος αναστολεα ασβεστιου και φαρμακευτικες συνθεσεις που τον περιεχουν
CL2007003396A1 (es) Uso de agomelatina o n-[2-(7-metoxi-1-naftil)etil]acetamida para el tratamiento del sindrome de smith magenis; composicion farmaceutica que contiene agomelatina.
CY1111257T1 (el) Χρηση της αγομελατινης για τη ληψη φαρμακων προοριζομενων για τη θεραπεια των διπολικων διαταραχων
CY1115587T1 (el) Μεθοδος και συνθεση για την θεραπεια παθησης με την μεσολαβηση ενος ληπτη σεροτονινης (sεrοτονιν)
CY1112223T1 (el) Συνδυασμος μεταξυ της αγομελατινης και ενος θυμορρυθμιστικου μεσου και οι φαρμακευτικες συνθεσεις που τον περιεχουν
AR067351A1 (es) Combinacion de picotamida con nafronil
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης
NO20076002L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi
CL2007002217A1 (es) Composicion farmaceutica que contiene saredutant con un inhibidor selectivo de la recaptacion de serotonina o con un inhibidor de la recaptacion de serotonina/norepinefrina; y uso en la prevencion y el tratamiento de un trastorno depresivo mayor.
NO20081723L (no) Assosiasjon av beta 3 reseotoragonist og monoamin gjenopptaksinhibator, farmasoytisk sammensetting inneholdende samme og terapeutisk anvendelse derav
CY1115436T1 (el) Αναστολεις της κινασης p70 s6
AR062981A1 (es) [2-(-fluor-1h-indol-3-ilsulfanil) bencil metilamina para el tratamiento de trastrornos afectivos